**B. Appendix 2. Detailed results of positive signals (FDR < 0.05; Specificity** ≥ **0.99) of mental disorders related with statins reported as adverse drug reaction (ADR) in Vigiaccess™ database and analyzed by a contrasted approach of Bayesian confidence propagation neural network (BCPNN) extended to the multiple comparison setting for active ingredients groups**

Interpretation of items: drug code: active ingredient reported; event effect: ADR reported; count: number of couples 'active ingredient-ADR' reported; post.H0: posterior probability of null hypothesis; FDR: false discovery rate; FNR: false negative rate; Se: Sensitivity (\* ≥ 0.20); Sp: Specificity.


*Insomnia; middle insomnia; terminal insomnia; sleep disorder; poor quality sleep.*

*Depression; major depression; depressed mood; depressive symptoms.*


*Amnesia; dementia; dementia Alzheimer's type; memory impairment.*



*Dreams disorders: nightmares; abnormal dreams, daydreaming.*

